IQVIA Holdings Inc. (IQV) – What Are Investment Firms Thinking About This Stock?

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Moderate Buy” from the seventeen brokerages that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $276.00.

Several equities analysts have recently commented on the stock. Morgan Stanley boosted their price target on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. UBS Group started coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada lifted their price objective on IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Finally, TD Cowen lifted their price objective on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th.

IQVIA Stock Performance

IQV stock opened at $267.00 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The stock has a market cap of $43.95 billion, a P/E ratio of 33.13, a P/E/G ratio of 2.32 and a beta of 1.17. The firm has a 50 day simple moving average of $260.76 and a 200 day simple moving average of $212.85. IQVIA has a 52 week low of $154.50 and a 52 week high of $277.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts anticipate that IQVIA will post 11.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 15,581 shares of company stock worth $3,796,021. Insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

A number of institutional investors have recently added to or reduced their stakes in IQV. BlackRock Inc. acquired a new position in shares of IQVIA during the 2nd quarter worth $2,811,292,000. Canada Pension Plan Investment Board bought a new position in shares of IQVIA during the 2nd quarter valued at $240,911,000. Bank of America Corp DE acquired a new stake in shares of IQVIA in the 2nd quarter valued at $235,551,000. Legal & General Group Plc acquired a new stake in shares of IQVIA in the 2nd quarter valued at $211,342,000. Finally, Bank of New York Mellon Corp bought a new stake in IQVIA in the second quarter worth $180,296,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.